Mallinckrodt Pharmaceuticals

Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and therapies, as well as nuclear imaging products. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; analgesics and hemostasis products; and central nervous system drugs. The company’s core strengths include the acquisition and management of highly regulated raw materials, and specialized chemistry, formulation and manufacturing capabilities. The company’s Specialty Brands segment includes branded medicines; its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the Nuclear Imaging segment includes nuclear imaging agents. Mallinckrodt Pharmaceuticals provides equal employment opportunities (EEO) to all employees and applicants for employment without regard to race, color, religion, gender, sexual orientation, gender identity, national origin, age, disability, veteran status, or genetics. In addition to federal law requirements, Mallinckrodt Pharmaceuticals complies with applicable state and local laws governing nondiscrimination in employment in every location in which the company has facilities. This policy applies to all terms and conditions of employment, including recruiting, hiring, placement, promotion, termination, layoff, recall, transfer, leaves of absence, compensation and training.
Company Growth (employees)
Surrey, GB
Size (employees)
4,500 (est)
Mallinckrodt Pharmaceuticals was founded in 1867 and is headquartered in Surrey, GB

Mallinckrodt Pharmaceuticals Office Locations

Mallinckrodt Pharmaceuticals has offices in Surrey, Hazelwood and Dublin
Surrey, GB (HQ)
Lotus Park The Causeway
Dublin, IE
Hazelwood, US
675 James S McDonnell Blvd

Mallinckrodt Pharmaceuticals Data and Metrics

Mallinckrodt Pharmaceuticals Financial Metrics

Mallinckrodt Pharmaceuticals's revenue was reported to be £64.2 m in FY, 2015 which is a 3% increase from the previous period.

Revenue (FY, 2015)

64.2 m

Revenue growth (FY, 2014 - FY, 2015), %


Gross profit (FY, 2015)

8.8 m

Gross profit margin (FY, 2015), %


Net income (FY, 2015)

1.9 m

Market capitalization (25-Jul-2017)

4.7 b

Closing share price (25-Jul-2017)


Cash (25-Sep-2015)

403 k
Mallinckrodt Pharmaceuticals's current market capitalization is $4.7 b.
GBPFY, 2013FY, 2014FY, 2015


89.7 m62.6 m64.2 m

Revenue growth, %


Cost of goods sold

79.8 m56.3 m55.4 m

Gross profit

9.9 m6.3 m8.8 m

Gross profit Margin, %


Operating expense total

5.8 m3.8 m6.8 m

Pre tax profit

3.8 m2.4 m2 m

Net Income

3 m1.9 m1.9 m
GBPFY, 2013FY, 2014FY, 2015


9.6 m1.4 m403 k

Accounts Receivable

11.1 m13.4 m12.4 m

Current Assets

43 m50.1 m53.5 m


87 k64 k44 k

Total Assets

43.1 m50.2 m53.5 m

Accounts Payable

70 k67 k60 k

Current Liabilities

4.4 m9.7 m9.7 m

Total Liabilities

4.5 m9.7 m9.7 m

Retained Earnings

3 m1.9 m1.9 m

Total Equity

38.6 m40.5 m43.9 m

Financial Leverage

1.1 x1.2 x1.2 x
GBPFY, 2013FY, 2014FY, 2015

Income Taxes Paid

(748 k)(528 k)(117 k)
GBPY, 2015


11.7 k

Financial Leverage

1.2 x

Mallinckrodt Pharmaceuticals Market Value History

Traffic Overview of Mallinckrodt Pharmaceuticals

Mallinckrodt Pharmaceuticals News and Updates

We dug into the drug company Martin Shkreli sold out to the feds, and man is it ugly

Medicare spent over $500 million on a drug called Acthar in 2015. The drug, which has never been tested by the Food and Drug Administration, is the only one in the top 20 for Medicare that isn't considered life-saving. Now investors are suing Mallinckrodt Pharmaceuticals b…

Mallinckrodt Pharmaceuticals Company Life and Culture

You may also be interested in